Genetic alternations and overexpression of MET are broadly observed in various cancer types such as lung cancer, breast cancer and glioblastoma, and abnormal activation of HGF-MET signaling is involved in tumor progression and metastasis [4,5]. This evidence concerns the gene MET and breast carcinoma.